Does erectile dysfunction drug use contribute to risky sexual behavior?

• 来源期刊: 亚洲男性学杂志(英文版)
• 年，卷（期）: 2010,（5）
• 页码范围: 626-627
• 页数: 2页
• 语种: 英文
• DOI: 10.1038/aja.2010.98

摘要

Erectile dysfunction (ED) is a common sexual problem affecting up to one-third of men through-out their lives. According to the Massachusetts Male Aging Study (MMAS), ED affects an estimated 52% of men between the ages of 40 and 70. With the approval of silde-nafil (USA in March 1998), the first phosphodiesterase type 5 (PDE-5) inhibitor to be made available for treatment of ED, and the subse-quent approval of vardenafil (USA in August 2003) and tadalafil (USA in November 2003), the PDE-5 inhibitor class of drugs has rapidly become the first-line therapy for ED of varying etiologies and se-verities.